Dr. Marlene R. Moster, MD

Dr. Moster practices at Henry Alexander Spratt MD, PA in Miami, Florida.

Dr. Moster's NPI, 1962475806, was assigned on February 10, 2006. Dr. Moster graduated from SUNY Upstate Medical University in 1979. Dr. Moster holds Pennsylvania license MD024149E.

Dr. Moster's primary practice is Henry Alexander Spratt MD, PA, at 18999 Biscayne Blvd, Miami, FL 33180 in Miami-Dade County. The practice phone is (786) 239-7350.

Dr. Moster's primary practice is Henry Alexander Spratt MD, PA in Miami, Florida. Dmand AI also links Dr. Moster to 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moster practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Moster's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Moster is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Moster's licenses on file in 4 states: Pennsylvania, New Jersey, Florida and Delaware.

Dmand AI lists cataract, cataract surgery with lens implant, eye infection or inflammation, glaucoma, glaucoma surgery, secondary membranaous cataract surgery and vision problems among the conditions Dr. Moster treats.

CMS data shows 397 Medicare services from Dr. Moster across 10 procedure codes in 2024, for 92 Medicare patients. Medicare paid $18,777 for them. Every service was in an office.

CMS counts 92 Medicare patients who saw Dr. Moster in 2024. The largest group is 75 to 84, with 44 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Moster's median patient age at 68, with 62% women.

In 2024, Dr. Moster wrote 1,793 Medicare Part D claims for 517 patients. 62% of them were for generic drugs. CMS names the drug for 1,695 of them, across 16 drugs with 11 or more claims each, at $181,492 in total drug cost. In 2023, CMS named 4,435 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Moster for performance year 2024, reported as part of a group.

Dmand AI links 147 papers to Dr. Moster, published from 2006 to 2025. 2023 was the busiest year, with 10. The most frequent topics are Intraocular Pressure, Glaucoma and Trabeculectomy. Dr. Moster has published most often in J Glaucoma. Dr. Moster's most frequent co-authors are Michael J. Pro, MD, Michael Waisbourd, MD and Natasha Nayak Kolomeyer, MD.

Dmand AI links Dr. Moster to 12 clinical trials, 2 of them phase 2/3 studies. 2 are still active or recruiting. Conditions studied include Glaucoma, Glaucoma, Open-Angle and Ocular Hypertension. Wills Eye sponsors the most, 9. Open Payments lists research payments to Dr. Moster that name 1 trial.

CMS Open Payments shows 866 general payments to Dr. Moster from 38 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 43% of the total. Bausch & Lomb Americas Inc. paid the most, $128,807. It also lists 1 research payment totaling $81 in 2023, naming 1 clinical trial.

Dmand AI lists 4 awards for Dr. Moster, most recently Philadelphia Magazine in 2014.

Dr. Moster graduated from SUNY Upstate Medical University in 1979. Dr. Moster is a member of AAO.

Dr. Moster is in network with 14 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.